Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyValentina Guarneri, PierFranco Conte, Antonino Musolino et al.|Journal of Clinical Oncology|2012Cited by 368
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2011Cited by 32
Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Cancer Research|2009Cited by 8
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trialValentina Guarneri, PierFranco Conte, Alberto Bottini et al.|Journal of Clinical Oncology|2009Cited by 3